Worldwide cancer mortality statistics continue to identify non-small cell lung cancer (NSCLC) as the predominant death caused by cancer.1 Recent therapeutic advances have centered on immune checkpoint blockade, particularly antibodies designed to target the PD-1 receptor and its corresponding ligand PD-L1. Here, CD274 is linked to non-small cell lung carcinoma.